Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urticaria

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504799-94-00

Acronym

EP-262-201

Enrollment

Registered

2023-12-28

Start date

2024-02-20

Completion date

2025-03-03

Last updated

2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Spontaneous Urticaria

Brief summary

The change in both itch intensity and number of hives.

Detailed description

Type, frequency, and severity of side effects related to the treatment., Change in vital signs, electrocardiograms (ECGs), and clinical laboratory parameters., Change in itch intensity., Change in number of hives.

Interventions

DRUGPlacebo

DRUGEP262

DRUG-

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The change in both itch intensity and number of hives.	—

Secondary

Measure	Time frame
Type, frequency, and severity of side effects related to the treatment., Change in vital signs, electrocardiograms (ECGs), and clinical laboratory parameters., Change in itch intensity., Change in number of hives.	—

Countries

Germany, Netherlands, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026